Fei Yang
Zhejiang University
14 Papers
19 Citations
Fei Yang is an academic researcher from Zhejiang University. The author has contributed to research in topics: Immune system & Interleukin 10. The author has an hindex of 10, co-authored 14 publications.
Chat about Author
Papers
EpCAM-dependent extracellular vesicles from intestinal epithelial cells maintain intestinal tract immune balance
Lingling Jiang,Yingying Shen,Danfeng Guo,Diya Yang,Jiajun Liu,Xuefeng Fei,Yunshan Yang,B.X. Zhang,Zhendong Lin,Fei Yang,Xiaojian Wang,Keyi Wang,Jianli Wang,Zhijian Cai +13 more
TL;DR: The authors show that extracellular vesicles released from intestinal epithelial cells stimulate T regulatory cells and immunosuppressive dendritic cells, indicating that EVs from IECs participate in maintaining the intestinal tract immune balance.
Exosomes with membrane-associated TGF-β1 from gene-modified dendritic cells inhibit murine EAE independently of MHC restriction.
Lei Yu,Fei Yang,Lingling Jiang,Yinghu Chen,Keyi Wang,Feng Xu,Yinxiang Wei,Xuetao Cao,Jianli Wang,Zhijian Cai +9 more
TL;DR: The results indicate that mTGF‐β1‐EXOs possess powerful immunosuppressive ability and can effectively inhibit the development and progression of EAE in different strains of mice.
84
Correction to: TGF-beta1 gene-modified, immature dendritic cells delay the development of inflammatory bowel disease by inducing CD4(+)Foxp3(+) regulatory T cells
TL;DR: Evidence is provided that TGF-β1-modified bone marrow-derived imDCs may have a therapeutic effect to IBD, and this effect is mediated partially by inducing CD4+Foxp3+ regulatory T cells in mesentery lymph nodes to control inflammation.
Activation‑induced upregulation of MMP9 in mast cells is a positive feedback mediator for mast cell activation
TL;DR: An upregulation of MMP9 protein and mRNA expression levels in mast cells activated by phorbol ester and ionomycin revealed a novel M MP9‑mediated mechanism underlying mast cell activation, thus providing novel ideas for AR therapy.
Enhanced Antitumor Efficacy of Integrin-targeted Oncolytic Adenovirus AxdAdB3-F/RGD on Bladder Cancer
TL;DR: E1A and E1B double-restricted oncolytic adenovirus with RGD fiber modification has enhanced infectivity and on colytic effects to CAR-deficient bladder cancers, suggesting the therapeutic potential of AxdAdB3-F/RGD for bladder cancers.
18